Results from phase I and II trials of BGJ398 and erdafitinib in this population reported response rates of 25–40%, and based on these findings, erdafitinib was FDA approved for FGFR2/3 aberrant bladder cancers in 2019 [23]. This evidence concerns the gene FGFR2 and urinary bladder carcinoma.